Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2 -V617F
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The majority of patients with myeloproliferative neoplasms (MPNs) carry a somatic JAK2-V617F mutation. Because additional mutations can precede JAK2-V617F, it is questioned whether JAK2-V617F alone can initiate MPN. Several mouse models have demonstrated that JAK2-V617F can cause MPN; however, in all these models disease was polyclonal. Conversely, cancer initiates at the single cell level, but attempts to recapitulate single-cell disease initiation in mice have thus far failed. We demonstrate by limiting dilution and single-cell transplantations that MPN disease, manifesting either as erythrocytosis or thrombocytosis, can be initiated clonally from a single cell carrying JAK2-V617F. However, only a subset of mice reconstituted from single hematopoietic stem cells (HSCs) displayed MPN phenotype. Expression of JAK2-V617F in HSCs promoted cell division and increased DNA damage. Higher JAK2-V617F expression correlated with a short-term HSC signature and increased myeloid bias in single-cell gene expression analyses. Lower JAK2-V617F expression in progenitor and stem cells was associated with the capacity to stably engraft in secondary recipients. Furthermore, long-term repopulating capacity was also present in a compartment with intermediate expression levels of lineage markers. Our studies demonstrate that MPN can be initiated from a single HSC and illustrate that JAK2-V617F has complex effects on HSC biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Kiel, M. J., Yilmaz, Ö. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005) · Cell · doi:10.1016/j.cell.2005.05.026 · Cited by 3,168
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003 · cited 2×
“Patients with ET or PMF that are negative for JAK2-V617F frequently carry acquired mutations in calreticulin (CALR; Klampfl et al., 2013; Nangalia et al., 2013) or MPL (Pikman et al.”
BackgroundMutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · cited 21×
“Lineage intermediate c-Kit+ Sca-1+ (LintSK) and lineage high c-Kit+ Sca-1+ (LhighSK) cells from WT;GFP+ donors failed to engraft, as expected (Fig.”
BackgroundInfluentialSomatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756 · cited 2×
“Patients with ET or PMF that are negative for JAK2-V617F frequently carry acquired mutations in calreticulin (CALR; Klampfl et al., 2013; Nangalia et al., 2013) or MPL (Pikman et al., 2006).”
BackgroundMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 2×
“T h e Jo u rn al o f E xp er im en ta l M ed ic in e on July 22, 2018jem.rupress.org Downloaded from http://doi.org/10.1084/jem.20131371Published Online: 6 October, 2014 | Supp Info: 2214 MPN initiation from a single stem cell | Lundberg et al. JEM Vol. 211, No. 11 Article 2215 JAK2-V617F as the sole genetic alteratio…”
BackgroundInfluentialThe purification and characterization of fetal liver hematopoietic stem cells
Morrison, S. J., Hemmati, H. D., Wandycz, A. M., & Weissman, I. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10302 · Cited by 611 · cited 1×
“Up-regulation of cell-surface lineage antigens could be related to increased cycling, as has been reported in fetal liver HSCs (Morrison et al., 1995) and in adult BM after 5-FU treatment (Randall and Weissman, 1997).”
Background
Cited by
Van Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.02.001 · Cited by 206
JAK2V617F-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure
Sano, S., Wang, Y., Yura, Y., Sano, M., Oshima, K., Yang, Y., Katanasaka, Y., Min, K.-D., Matsuura, S., Ravid, K., et al. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.013 · Cited by 170
“Consistent with these findings, a model of Jak2 knock-in mice also display a myeloid bias of cell expansion (50,51).”
ResultMyeloproliferative neoplasm stem cells
Mead, A. J., & Mullally, A. (2017) · Blood · doi:10.1182/blood-2016-10-696005 · Cited by 169
Fuster, J. J., & Walsh, K. (2018) · Circulation Research · doi:10.1161/circresaha.117.312115 · Cited by 162
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Edelmann, B., Gupta, N., Schnoeder, T. M., Oelschlegel, A. M., Shahzad, K., Goldschmidt, J., Philipsen, L., Weinert, S., Ghosh, A., Saalfeld, F. C., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci90312 · Cited by 138
Metadata
- Authors
- Lundberg, P., Takizawa, H., Kubovcakova, L., Guo, G., Hao-Shen, H., Dirnhofer, S., Orkin, S. H., Manz, M. G., & Skoda, R. C.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-10-06
- Volume
- 211
- Issue
- 11
- Pages
- 2213-2230
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2151753421
- Cited by
- 106
- References
- 9
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2 -V617F. https://app.cochat.ai/papers/10.1084/jem.20131371
- The paper
- Lundberg, P., Takizawa, H., Kubovcakova, L., Guo, G., Hao-Shen, H., Dirnhofer, S., Orkin, S. H., Manz, M. G., & Skoda, R. C. (2014). Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2 -V617F. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20131371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.